370 related articles for article (PubMed ID: 26481868)
21. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Orouji E; Federico A; Larribère L; Novak D; Lipka DB; Assenov Y; Sachindra S; Hüser L; Granados K; Gebhardt C; Plass C; Umansky V; Utikal J
Int J Cancer; 2019 Dec; 145(12):3462-3477. PubMed ID: 31131878
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
23. SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression.
Zhou Z; Chen Z; Zhou Q; Meng S; Shi J; Mui S; Jiang H; Lin J; He G; Li W; Zhang J; Wang J; He C; Yan Y; Xiao Z
Cancer Sci; 2024 May; 115(5):1587-1601. PubMed ID: 38438251
[TBL] [Abstract][Full Text] [Related]
24. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
25. High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Zhou Z; Wu B; Tang X; Yang W; Zou Q; Wang H
Med Sci Monit; 2020 Apr; 26():e922982. PubMed ID: 32305991
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686.
Wu BH; Chen H; Cai CM; Fang JZ; Wu CC; Huang LY; Wang L; Han ZG
Oncotarget; 2016 Feb; 7(6):6847-63. PubMed ID: 26760772
[TBL] [Abstract][Full Text] [Related]
27. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.
Xu L; Feng X; Hao X; Wang P; Zhang Y; Zheng X; Li L; Ren S; Zhang M; Xu M
J Exp Clin Cancer Res; 2019 Feb; 38(1):98. PubMed ID: 30795787
[TBL] [Abstract][Full Text] [Related]
28. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
29. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.
Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY
Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646
[TBL] [Abstract][Full Text] [Related]
30. SETDB1 regulates SMAD7 expression for breast cancer metastasis.
Ryu TY; Kim K; Kim SK; Oh JH; Min JK; Jung CR; Son MY; Kim DS; Cho HS
BMB Rep; 2019 Feb; 52(2):139-144. PubMed ID: 30545440
[TBL] [Abstract][Full Text] [Related]
31. HBx represses RIZ1 expression by DNA methyltransferase 1 involvement in decreased miR-152 in hepatocellular carcinoma.
Zhao Z; Hu Y; Shen X; Lao Y; Zhang L; Qiu X; Hu J; Gong P; Cui H; Lu S; Zheng Y; Zhou M; Fan H
Oncol Rep; 2017 May; 37(5):2811-2818. PubMed ID: 28339081
[TBL] [Abstract][Full Text] [Related]
32. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
33. SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer.
Prashanth S; Radha Maniswami R; Rajajeyabalachandran G; Jegatheesan SK
Drug Discov Today; 2024 May; 29(5):103982. PubMed ID: 38614159
[TBL] [Abstract][Full Text] [Related]
34. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Fei Q; Shang K; Zhang J; Chuai S; Kong D; Zhou T; Fu S; Liang Y; Li C; Chen Z; Zhao Y; Yu Z; Huang Z; Hu M; Ying H; Chen Z; Zhang Y; Xing F; Zhu J; Xu H; Zhao K; Lu C; Atadja P; Xiao ZX; Li E; Shou J
Nat Commun; 2015 Oct; 6():8651. PubMed ID: 26471002
[TBL] [Abstract][Full Text] [Related]
35. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Zhou Z; Jiang H; Tu K; Yu W; Zhang J; Hu Z; Zhang H; Hao D; Huang P; Wang J; Wang A; Xiao Z; He C
J Exp Clin Cancer Res; 2019 Jan; 38(1):18. PubMed ID: 30646949
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma.
Zhang L; Yang F; Yuan JH; Yuan SX; Zhou WP; Huo XS; Xu D; Bi HS; Wang F; Sun SH
Carcinogenesis; 2013 Mar; 34(3):577-86. PubMed ID: 23222811
[TBL] [Abstract][Full Text] [Related]
37. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
38. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma.
Wu J; Qiao K; Du Y; Zhang X; Cheng H; Peng L; Guo Z
Sci Rep; 2020 Mar; 10(1):4490. PubMed ID: 32161353
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
